About Hilary Weingarden, PhD
Hilary Weingarden, Ph.D. is an Assistant Professor at Harvard Medical School and a psychologist in the Center for OCD and Related Disorders (CORD) at Massachusetts General Hospital (MGH). Dr. Weingarden received her bachelor’s degree from Tufts University and her Ph.D. in clinical psychology from George Mason University. She completed her pre- and post-doctoral training at MGH/Harvard Medical School, within the Center for OCD and Related Disorders (CORD) and is a licensed psychologist in the state of Massachusetts.
Dr. Weingarden's research is focused on cognitive and emotional risk factors for adverse outcomes such as suicide risk in OCD and body dysmorphic disorder (BDD). Her research also focuses on applying technology to enhance assessment of and interventions for OCD and related disorders. Her work has been supported as Principal Investigator by the National Institute of Mental Health, Harvard Medical School, and as a co-Investigator on industry collaborations. In addition to her work at MGH, she has a private practice where she provides evidence-based psychological treatments for adults with OCD and related disorders.
For more details about my work and research, please visit my website.
Clinical Interests:
- Anxiety disorders
- Body dysmorphic disorder
- Obsessive Compulsive Disorder (OCD)
- Obsessive compulsive spectrum disorders
Treats:
- Adult
Locations
Mass General Psychiatry: Adult Outpatient Psychiatry Services
55 Fruit St.
Wang Ambulatory Care Center
Boston, MA 02114
Phone: 617-724-7792
Medical Education
- PhD, George Mason University
- Residency, Massachusetts General Hospital*
Accepted Insurance Plans
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna Behavioral Health
- MassHealth
- Medicare
- Medicare - ACD
- Medicare ACO - ACD
- Medicare ACO - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Vermont
- TriCare
- United Behavioral Health
- United Behavioral Health - MGH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Weingarden's research interests are broadly focused on cognitive and emotional risk factors for poor psychosocial outcomes in individuals with obsessive-compulsive related disorders (OCRDs) and body image disturbances. She is particularly interested in the roles of shame and other non-anxiety emotions (e.g., disgust, guilt) in OCRDs. Dr. Weingarden is also interested in issues of access to empirically supported treatments and how technology may be used to improve treatment access.
For more details about my research, please visit my website.
Publications
-
Selected recent publications:
Weingarden H, Hoeppner SS, Snorrason I, Greenberg JL, Phillips KA, Wilhelm S (in press). Rates of remission, sustained remission, and recurrence in a randomized controlled trial of cognitive behavioral therapy versus supportive psychotherapy for body dysmorphic disorder. Depression & Anxiety.
Weingarden H, Matic A, Garriga Calleja R, Greenberg JL, Harrison O, Wilhelm S (2020). Optimizing smartphone cognitive behavioral therapy for body dysmorphic disorder using passive smartphone data: Initial insights from a pilot trial. JMIR mHealth & uHealth.
Wilhelm S, Weingarden H, Ladis I, Braddick V, Shin J, Jacobson NC (2020). Cognitive-behavioral therapy in the digital age: Presidential Address. Behavior Therapy, 51(1), 1-14.
Wilhelm S, Weingarden H, Greenberg J, Ladis I, McCoy T, Summers B, Matic A, Harrison O. (2020). Development and pilot testing of smartphone-delivered cognitive behavioral therapy for body dysmorphic disorder: Preliminary feasibility, acceptability, and efficacy. Behavior Therapy, 51, 15-26.
†Greenberg JL, †Weingarden H, Wilhelm S. (2019). A practical guide to managing body dysmorphic disorder in the cosmetic surgery setting. JAMA Facial Plastic Surgery, 21, 181-182.
†Co-first authors
Jacobson NC, Weingarden H, Wilhelm S. (2019). Digital biomarkers of mood disorders and symptom change. npj Digital Medicine, 2, 3.